101. Spectral-Domain OCT Analyses of Macular Changes After Ranibizumab Therapy for Type 1 Retinopathy of Prematurity
- Author
-
Ahmet Burak Bilgin, Berna Dogan, Muhammet Kazim Erol, Ozdemir Ozdemir, Zuhal Özen Tunay, and Deniz Turgut Coban
- Subjects
Male ,Vascular Endothelial Growth Factor A ,medicine.medical_specialty ,genetic structures ,Visual Acuity ,Foveal thickness ,Spectral domain ,Angiogenesis Inhibitors ,Gestational Age ,Serous Retinal Detachment ,Macular Edema ,Ophthalmology ,Ranibizumab ,medicine ,Humans ,Infant, Very Low Birth Weight ,Macula Lutea ,Retinopathy of Prematurity ,Macular edema ,Retrospective Studies ,Retinal pigment epithelium ,business.industry ,Infant, Newborn ,Infant ,Retinopathy of prematurity ,General Medicine ,medicine.disease ,eye diseases ,medicine.anatomical_structure ,Pediatrics, Perinatology and Child Health ,Intravitreal Injections ,Female ,sense organs ,Indirect ophthalmoscope ,business ,Infant, Premature ,Tomography, Optical Coherence ,medicine.drug - Abstract
Purpose: To investigate the clinical and macular spectral-domain optical coherence tomography (SD-OCT) findings after intravitreal ranibizumab treatment for type 1 retinopathy of prematurity (ROP). Methods: Eighteen eyes of 10 premature infants with type 1 ROP were retrospectively studied. All eyes were treated with intravitreal ranibizumab as monotherapy. Macular SD-OCT was performed before and after intravitreal ranibizumab therapy using a portable SD-OCT machine; the follow-up images were taken 1 day, 1 week, 1 month, and 2 months after therapy. Results: Among the 10 infants, there were six males and four females. Mean central foveal thickness before and 2 months after intravitreal ranibizumab was 292.5 ± 61.4 and 171.6 ± 21.7 µm, respectively. Differences were statistically significant ( P = .01). Sixteen eyes of eight patients had macular edema before treatment. Two eyes of two patients developed a crack in the outer hyperreflective line on SD-OCT corresponding with retinal pigment epithelium with serous retinal detachment 1 day after treatment. Macular edema regressed in all patients 2 months after intravitreal ranibizumab therapy. Mean follow-up time was 11.4 ± 1.5 months. No recurrence was seen except in both eyes of one patient treated with intravitreal ranibizumab monotherapy. Conclusions: Intravitreal ranibizumab injection is effective for the treatment of type 1 ROP as a monotherapy agent; however, macular changes not seen with indirect ophthalmoscope may develop. [ J Pediatr Ophthalmol Strabismus. 2015;52(3):152–158.]
- Published
- 2014